Glenmark launches hydrocortisone butyrate cream in US

Glenmark Generics Inc, USA, the subsidiary of Glenmark Generics Ltd, has launched its hydrocortisone butyrate cream USP, 0.1% in the US. The company received approval from the US FDA for abbreviated new drug application (ANDA) for its generic version of Locoid Lipocream on September 27, 2013. Glenmark is entitled to 180 days of exclusivity as it is the first generic company to file an ANDA for the product.
 
ALSO READ: Kanoria Chemicals to form JV with US-based Momentive Specialty Chemicals

Hydrocortisone butyrate cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults and the treatment of mild to moderate atopic dermatitis in patients 3 months to 18 years of age. According to IMS Health sales data for the 12 month period ending September 2013, hydrocortisone butyrate cream garnered annual sales of approximately $ 36.8 million.
 
Glenmark Generics Ltd is a subsidiary of Glenmark Pharmaceuticals Ltd.